Low-molecular-weight heparins in the management of acute coronary syndromes

Archives of Internal Medicine

Volumn 159, Issue 16, 1999, Pages 1849-1857

  Zed, Peter J ^a   Tisdale, James E ^b,c,d,e,f,g   Borzak, Steven ^c  

^a VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^b WAYNE STATE UNIVERSITY   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d SANOFI   (France)

^e PFIZER INC   (United States)

^f MILLENNIUM PHARMACEUTICALS INC   (United States)

^g 3M COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARDEPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; HEART INFARCTION; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; UNSTABLE ANGINA PECTORIS;

EID: 0033552105     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.16.1849     Document Type: Review

References (89)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250.
2. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105-1111.
3. The RISC Group. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827-830.
4. Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 1993;88:2045-2048.
5. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS trial. Circulation. 1994;89:81-88.
6. Neri Serneri GG, Modesti PA, Gensini GF, et al. Randomized comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Lancet. 1995;345:1201-1204.
7. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 1992;327: 141-145.
8. Holdright D, Patel D, Cunningham D, et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol. 1994;24:39-45.
9. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995;108(suppl): 258S-275S.
10. Ofosu FA, Modi GJ, Hirsh J, Buchanan MR, Blajchman MA. Mechanisms for inhibition of the generation of thrombin activated by sulfated polysaccharides. Ann N Y Acad Sci. 1986;485:41-55.
11. Ofosu FA, Esmon CT, Blajchman MA, et al. Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J. 1989;257:143-150.
12. Beguin S, Mardiguian J, Lindhout T, Hemker HC. The mode of action of low molecular weight heparin preparation (PK 10169) and two of its major components on thrombin generation in plasma. Thromb Haemost 1989;61:30-34.
13. Beguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost. 1989;60:457-462.
14. Danielsson A, Raub E, Lindahl U, Bjork I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem. 1986;261:15467-15473.
15. Jordon RE, Oosta GM, Gardner WT, Rosenberg RD. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low-molecular-weight heparin. J Biol Chem. 1980; 255:10081-10090.
16. Hommes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis: a meta-analysis. Ann Intern Med. 1992;116:279-284.
17. Young E, Prins MH, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost. 1992;67:639-643.
18. Bjornsson TO, Wolfram KM, Kitchell BB. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther. 1982;31:104-113.
19. De Swart CAM, Nijmeyer B, Roelofs JMM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood. 1982;60:1251-1258.
20. Singer RL, Mannion JD, Bauer TL, Armenti FR, Edie RN. Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass. Chest. 1993;104:1436-1440.
21. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
22. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis, frequency, avoidance and management. Drug Saf. 1997;17:325-341.
23. Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ. Heparin-induced thrombocytopenia. J Am Coll Cardiol. 1998;31:1449-1459.
24. Griffith CC, Nichols G, Asher JD, Flanagan B. Heparin osteoporosis. JAMA. 1965;193:85-88.
25. Howell R, Fidler J, Letsky E, de Swiet M. The risks of antenatal subcutaneous heparin prophylaxis: a controlled-trial. Br J Obstet Gynaecol. 1983;90: 1124-1128.
26. Dahlman T, Lindvall N, Hellgren M. Osteopenia in pregnancy during long-term heparin treatment: a radiological study post-partum. Br J Obstet Gynaecol. 1990;97:221-228.
27. Ginsberg JS, Kowalchuck G, Hirsh J, et al. Heparin effect on bone density. Thromb Haemost. 1990;64:286-289.
28. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79:1-17.
29. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688-698.
30. Turpie AGG. Pharmacology of the low-molecular-weight heparins. Am Heart J. 1998;135:S329-S335.
31. Martineau P, Tawil N. Low-molecular-weight heparins in the treatment of deep-vein thrombosis. Ann Pharmacother. 1998;32:588-601.
32. Barrowcliffe TW, Merton RE, Havercrott SJ, Thunberg L, Lindahl U, Thomas DP. Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides. Thromb Res. 1984;34:125-133.
33. Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem. 1986;261:3980-3986.
34. Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low-molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost. 1994;71:300-304.
35. Young E, Cosmi B, Weitz J, Hirsch J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (enoxaparin) to plasma proteins. Thromb Haemost. 1993; 70:625-630.
36. Harenberg J. Pharmacology of low molecular weight heparins. Semin Thromb Hemost. 1990; 16(suppl):12-18.
37. Matzsch T, Bergquist D, Hedner U, Ostergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost. 1987;57: 97-101.
38. Boneu B, Caranobe C, Cadroy Y, et al. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Semin Thromb Hemost. 1988;14:18-27.
39. Bergqvist D, Nilsson B, Hedner U, Pederson PC, Ostergaard PB. The effects of heparin fragments of different molecular weights on experimental thrombosis and haemostasis. Thromb Res. 1985; 38:589-601.
40. Carter CJ, Kelton JG, Hirsch J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparins in rabbits. Blood. 1982; 59:1339-1345.
41. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest. 1980; 65:64-73.
42. Horne MK III, Chao ES. The effect of molecular weight on heparin binding to platelets. Br J Haematol. 1990;74:306-312.
43. Blajchman MA, Young E, Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann N Y Acad Sci. 1989;556:245-254.
44. Sobel M, McNeill PM, Carlson PL, et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest. 1991;87:1787-1793.
45. de Romeuf C, Mazurier C. Heparin binding assay of von Willebrand factor (vWF) in plasma milieu: evidence of the importance of the mutimerization degree of vWF. Thromb Haemost. 1993;69: 436-440.
46. Leizororovicz A, Simonneau G, Decousis H, Boissel JP. Comparison of efficacy and safety of low-molecular-weight heparins and unfractionated heparin in initial treatment of venous thrombosis: a meta-analysis. BMJ. 1994;309:299-304.
47. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med. 1996;100:269-277.
48. Lensing AWA, Prins MH, Davidscn BL, Hirsch J. Treatment of deep-vein thrombosis with low molecular-weight-heparins: a meta-analysis. Arch Intern Med 1995;155:601-607.
49. Andersen DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep-vein thrombosis after total hip arthroplasty. Ann Intern Med. 1993;119:1105-1112.
50. Lassen MR, Borris LC, Christiansen HM, et al. Clinical trials with low molecular weight heparins in the prevention of postoperative thromboembolic complications: a meta-analysis. Semin Thromb Hemost. 1991;17(suppl 3):284-290.
51. Nuromohamed MT, Rosendaal FR, Buller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopedic surgery: a meta-analysis. Lancet. 1992;340:152-156.
52. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med. 1992; 326:975-982.
53. Bergqvist D, Burmark US, Frisell J, et al. Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low-dose heparin. Semin Thromb Hemost. 1990;16 (suppl):19-24.
54. Bergqvist D, Burmark US, Frisell J, et al. Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications. Haemostasis. 1986;16(suppl 2):11-18.
55. Levine M, Gent M, Hirsch J, et al. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
56. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared to subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334:682-687.
57. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447-452.
58. The Columbus Investigators. Low-molecular weight heparin in the treatment of patients with venous thromboembolism. N Eng J Med. 1997; 337:657-662.
59. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular weight heparin with unfractionated heparin for acute pulmonary embolism. N Eng J Med. 1997;337:663-669.
60. Kakker W, Cohen AT, Edmonson RA, et al. Low molecular weight heparin versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet. 1993;341:259-265.
61. Turpie AGG, Levine MN, Hirsch J, et al. A randomized controlled trial of a low-molecular weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986;315:925-929.
62. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med. 1996;124:619-626.
63. Green D. Prophylaxis of thromboembolism in spinal-card injured patients. Chest 1994;102(suppl A):649S-651S.
64. Green D, Lee Y, Ito VY, et al. Fixed-vs. adjusted-dose heparin in the prophylaxis of thromboembolism in spinal cord injury. JAMA. 1988;260: 1255-1258.
65. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996; 335:701-707.
66. Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly inpatients bedridden for an acute illness. Thromb Haemost. 1996;76:529-534.
67. Harenberg J, Kallenbach B, Martin U, et al. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res. 1990;59:639-650.
68. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med. 1985; 313:1369-1375.
69. Lewis H Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309:396-403.
70. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA. 1996;276: 811-815.
71. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol. 1995;26:313-318.
72. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 1996;347:561-568.
73. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation. 1997;96: 61-68.
74. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol. 1997;29:1474-1482.
75. Antman EM and the Thrombolyis in Myocardial Infarction (TIMI) Investigators, TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial: rationale, study design, and methods. Am Heart J. 1998;135:S353-S360.
76. Leizorovicz A. The FRAXIS study: optimal duration of treatment of unstable angina in the acute phase - preliminary results [abstract]. Presented at: 20th Congress of the European Society of Cardiology; August 22-26, 1998; Vienna, Austria.
77. Antman EM, McCabe CH, Premmereur J, et al. Enoxaparin for the acute and chronic management of unstable angina/non-Q wave myocardial infarction: results of TIMI 11B [abstract]. Circulation. 1998;98(suppl 1):1-504.
78. Ferguson JJ. Meeting highlights: 47th annual scientific sessions of the American College of Cardiology. Circulation. 1998;97:2377-2381.
79. Raschke RA, Reilly RM, Guidry JR, Fontana JR, Srinivas S. The weight based heparin nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med. 1993; 119:874-881.
80. Becker RC, Ball SP, Eisenberg P, et al. A randomized trial of weight-adjusted intravenous heparin dose titrationand point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Am Heart J. 1999;137:59-71.
81. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation. 1998; 97:1702-1707.
82. Balen RM, Marra CA, Zed PJ, Cohen M, Frighetto L. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes: a Canadian hospital perspective. Pharmacoeconomics. In press.
83. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-1497.
84. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498-1505.
85. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation. 1998;97:2386-2395.
86. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation. N Engl J Med. 1998; 339:436-443.
87. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996;335:775-782.
88. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation. 1996;94:911-921.
89. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet. 1999;353: 429-438.